In the UK, the National Institute for Clinical Excellence has announced revisions to its initial, draft recommendation on the clinical use of denosumab (Xgeva®) for the treatment of people with cancer that has metastasized to the bones. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: denosumab, NICE, skeletal-related events, Xgeva | Leave a comment »
Denosumab (Xgeva®) has been approved by the European Medicines Agency (EMEA) for the prevention of skeletal-related events (SREs) in adults with bone metastases from solid tumors, including prostate cancer, according to a media release issued by Amgen last Friday. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: denosumab, Europe, skeletal-related events | Leave a comment »
According to a media release from Amgen, issued late yesterday, the US Food & Drug Administration (FDA) has approved denosumab (to be known by the brand name Xgeva™) for “prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.” This indication would include patients with prostate cancer and evident bone metastasis. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Prevention | Tagged: approval, denosumab, fracture, skeletal-related events, Xgeva | 1 Comment »
Saturday was never going to be a major day for prostate cancer at the annual meeting of the American Society for Clinical Oncology (ASCO) here in Chicago. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Risk | Tagged: denosumab, skeletal-related events, zoledronate | Leave a comment »
Amgen, the developer of denosumab (also known as RANK-L) has released data today from a head-to-head trial of their drug vs. zoledronate (Zometa) in the management of patients with advanced breast cancer and bone metastases. … READ MORE …
Filed under: Drugs in development | Tagged: denosumab, skeletal-related events, SREs, zoledronate | Leave a comment »
Items covered in this weekend news report include:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: acrylamide, bone turnover markers, brachytherapy, carcinogen, estramustine, etopside, external beam radiation, HRPC, risk, skeletal-related events, SREs, surgery | Leave a comment »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK